三、被担保人基本情况 证券代码：300981 证券简称：中红医疗 公告编号：2026-013 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2025 年 12 月 8 日、2025 年 12 月 25 日召开第四届董事会第十五次会议、2025 年第四次临 时股东会，审议通过了《关于公司及子公司 2026 年度向银行申请综合授信额度 暨公司为子公司申请综合授信额度提供担保的议案》，同意公司为控股子公司 2026 年度向金融机构申请的授信额度提供担保，担保额度总计不超过 25 亿元， 其中，为资产负债率 70%（含）以上的控股子公司提供担保额度为不超过 15 亿 元。具体内容详见《关于公司及子公司 2026 年度向银行申请综合授信额度暨公 司为子公司申请综合授信额度提供担保的公告》（公告编号：2025-105）。 二、担保进展情况 近日，公司控股子公司深圳迈德瑞纳生物科技有限公司（以下简称"迈德瑞 纳"或"授信申请人"）为满足业 ...

Core Viewpoint - Zhonghong Medical is focusing on innovation and digital technology integration to develop high-performance medical products, aiming to become a leading provider of intelligent medical solutions in the industry [2]. Group 1: Company Overview - Zhonghong Medical is primarily engaged in the research, production, and sales of high-quality disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, located in Tangshan, Hebei Province [9]. Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% year-on-year [10]. - As of September 30, 2025, the company had a total market capitalization of 5.665 billion yuan [1]. Group 3: Market Position and Strategy - The company exports 81.56% of its revenue, benefiting from the depreciation of the RMB [4]. - Zhonghong Medical employs an ODM direct sales model, producing medical devices and consumables for overseas brand owners, who handle packaging and sales [2]. Group 4: Recent Developments - Zhonghong Medical showcased its products at the 12th Beijing Pet Expo, highlighting its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, catering to various clinical scenarios [3].

Core Viewpoint - Zhonghong Medical (300981) has shown a mixed performance in terms of stock price and financial results, with a recent stock price increase but declining profits and revenues in the latest quarterly report [1][3]. Group 1: Stock Performance - As of February 10, 2026, Zhonghong Medical's stock closed at 13.54 yuan, up by 3.28%, with a turnover rate of 2.05% and a trading volume of 80,700 shares, amounting to a total transaction value of 109 million yuan [1]. - On the same day, the net inflow of main funds was 14.4651 million yuan, accounting for 13.26% of the total transaction value, while retail investors saw a net outflow of 11.2646 million yuan, representing 10.33% of the total [1]. Group 2: Financing and Margin Trading - In the financing and margin trading segment, on February 10, 2026, the financing buy amounted to 20.7183 million yuan, with a financing repayment of 11.4878 million yuan, resulting in a net financing increase of 9.2305 million yuan [2]. - The margin trading data indicates that 4,100 shares were sold short, with no shares being repaid, leaving a short balance of 35.52 million yuan and a total margin trading balance of 127 million yuan [2]. Group 3: Financial Performance - According to the Q3 2025 report, Zhonghong Medical's main revenue for the first three quarters was 1.864 billion yuan, reflecting a year-on-year increase of 1.38%, while the net profit attributable to shareholders was -7.2102 million yuan, a decline of 114.13% [3]. - The third quarter alone saw a revenue of 626 million yuan, down by 9.24% year-on-year, with a net profit of -12.9531 million yuan, a decrease of 170.01% [3]. - The company reported a debt ratio of 28.02%, investment income of 8.7618 million yuan, financial expenses of -17.6741 million yuan, and a gross profit margin of 10.54% [3].

Core Viewpoint - Zhonghong Medical has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth opportunities in the medical device sector [1]. Group 1: Company Overview - Zhonghong Medical primarily focuses on ODM production for overseas medical devices and consumables, responsible for product design and manufacturing while brand owners handle packaging and sales [2]. - The company is a state-owned enterprise controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - Zhonghong Medical specializes in high-quality disposable protective gloves and medical consumables, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. - The company's overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Product Innovation and Market Presence - Zhonghong Medical showcased its innovative products at the 12th Beijing Pet Expo, including the Medrayna veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing multiple infusion modes and safety [3]. - The company aims to integrate digital technology into product development and smart upgrades, striving to become a leading provider of innovative medical solutions [2]. Group 4: Market Activity - The stock experienced a net inflow of 13.98 million yuan today, with a trading volume of 1.09 billion yuan and a turnover rate of 2.05% [1][6]. - The average trading cost of the stock is 14.22 yuan, with the current price near a support level of 13.54 yuan, indicating potential for price fluctuations [8].

Core Viewpoint - Zhonghong Medical is focusing on innovation and digital transformation in the medical device sector, with a significant portion of its revenue coming from overseas markets, benefiting from the depreciation of the RMB. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9] - The company was established on December 22, 2010, and went public on April 27, 2021 [9] - As of September 30, 2025, Zhonghong Medical had 22,400 shareholders, an increase of 11.24% from the previous period [10] Group 2: Financial Performance - For the period from January to September 2025, Zhonghong Medical achieved a revenue of 1.864 billion yuan, representing a year-on-year growth of 1.38% [10] - The net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [10] - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed over the past three years [11] Group 3: Market Position and Strategy - The company primarily exports its products and operates under an ODM direct sales model, producing for overseas brand owners [2] - Zhonghong Medical is committed to integrating innovation and learning to develop high-performance medical products that meet diverse market needs [3] - The company is positioned as a state-owned enterprise, with its ultimate control held by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5] Group 4: Product Highlights - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its innovative veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing multiple infusion modes and safety [2] - The infusion pumps received positive feedback from veterinarians for their ease of use and adaptability to various clinical scenarios [2] Group 5: Market Trends - The company is part of the medical device industry, specifically in the medical consumables sector, and is influenced by trends in the pet economy, smart healthcare, and the depreciation of the RMB [2]

Core Viewpoint - The company, Zhonghong Medical, is primarily engaged in the export of medical devices and consumables, utilizing an ODM direct sales model, which allows it to design and produce products for overseas brand owners [2][4]. Group 1: Business Overview - Zhonghong Medical's main business includes the research, production, and sales of high-quality disposable protective gloves, with health protection products accounting for 89.48% of revenue, safety infusion products 6.22%, and innovative incubation products 4.30% [9]. - The company has a significant international presence, with 81.56% of its revenue coming from overseas markets, benefiting from the depreciation of the RMB [4]. Group 2: Product Innovation and Market Presence - The company showcased its products at the 12th Beijing Pet Expo, highlighting its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing multiple infusion modes and safety [2]. - Zhonghong Medical emphasizes innovation through digital technology, aiming to develop high-quality, innovative medical consumables and equipment, positioning itself as a leading provider of intelligent medical solutions [3]. Group 3: Financial Performance - For the period from January to September 2025, Zhonghong Medical reported revenue of 1.864 billion yuan, a year-on-year increase of 1.38%, while the net profit attributable to shareholders was a loss of 7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed over the past three years [11].

Key Points - The stock price of Zhonghong Medical (300981) closed at 12.93 yuan on February 5, 2026, with a slight increase of 0.31% and a turnover rate of 0.6% [1] - The trading volume was 23,600 shares, with a total transaction amount of 30.4488 million yuan [1] Trading Information Summary - On February 5, 2026, the net inflow of main funds was 232,200 yuan, while the net inflow of speculative funds was 1.8918 million yuan; retail investors experienced a net outflow of 2.124 million yuan [1][3] Company Announcement Summary - Zhonghong Medical held its first extraordinary general meeting of shareholders for 2026 on February 5, 2026, where three proposals were approved: 1. Investment of idle self-owned funds in low-risk financial products for 2026 2. Conducting foreign exchange derivative trading for 2026 3. Engaging in commodity futures hedging business and related transactions for 2026 - All proposals were passed with the related shareholders abstaining from voting on the related transaction proposal [1][3] - A legal opinion from Beijing Deheng Law Firm confirmed the legality and validity of the meeting's procedures and voting results [1]

2. 本次股东会不涉及变更以往股东会已通过决议的情形。 证券代码：300981 证券简称：中红医疗 公告编号：2026-012 中红普林医疗用品股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1. 本次股东会没有出现否决提案的情形。 3. 会议召开方式：现场表决与网络投票相结合的方式。 4. 会议召集人：公司董事会。 5. 会议主持人：董事长桑树军先生。 一、会议召开情况和出席情况 1. 会议召开时间： 现场会议召开时间：2026 年 2 月 5 日（星期四）14:30； 网络投票时间：2026 年 2 月 5 日。其中，通过深交所交易系统进行网络投 票的时间为 2026 年 2 月 5 日 9:15－9:25，9:30－11:30 和 13:00－15:00；通过 深圳证券交易所互联网系统投票的具体时间为 2026 年 2 月 5 日 9:15－15:00。 2. 现场会议召开地点：北京经济技术开发区科创六街 87 号四楼会议室。 6. 本次股东会的召集及召开符合《中华人民共和国公司法》等相关法 ...

北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2026 年第一次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2026 年第一次临时股东会的法律意见 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2026 年第一次临时股东会的 法律意见 德恒 01G20250295-05 号 致：中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）2026 年第一次临时 股东会（以下简称"本次会议"）于 2026 年 2 月 5 日（星期四）召开。北京德 恒律师事务所（以下简称"德恒"）受公司委托，指派崔满长律师、王瑞芸律师 （以下简称"德恒律师"），根据《中华人民共和国证券法》（以下简称"《证 券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、中国证 券监督管理委员会《上市公司股东会规则》（以下简称"《股东会规则》"）、 《中红普林医疗用品股份有限公司章程》（以下简称"《公司章程》"）的规定， 就本 ...

Core Viewpoint - Zhonghong Medical is experiencing growth in its stock performance and is positioned to benefit from various market trends, including the pet economy and digital transformation in healthcare [1][2][4]. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9]. - As of September 30, 2025, Zhonghong Medical reported a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to shareholders was -7.21 million yuan, a decrease of 114.13% compared to the previous year [10]. Group 2: Market Position and Trends - The company primarily focuses on export sales, utilizing an ODM direct sales model, where it produces medical devices and consumables for overseas brand owners [2]. - Zhonghong Medical's overseas revenue accounted for 81.56% of its total revenue, benefiting from the depreciation of the Chinese yuan [4]. - The company is recognized as a state-owned enterprise, with its ultimate control held by the State-owned Assets Supervision and Administration Commission of the Xiamen Municipal Government [5]. Group 3: Product Innovations and Developments - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its innovative veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, catering to various clinical scenarios [2]. - The company emphasizes innovation through digital technology integration, aiming to develop high-quality, innovative medical consumables and equipment [3].